Pfizer bets $7.3 billion on obesity drugs with Metsera buy
Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications...
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached...
Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipeline
Pfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in cas...
1 Reason Every Investor Should Know About Pfizer (PFE) Stock
If you're a long-term investor, why should you be paying closer attention to pharmaceutical giant Pfizer (PFE -3.98%)? Because of its dividend, of course!
Pfizer, Moderna shares plunge on report that Trump officials plan to link 25 child deaths to COVID vaccine
Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively.
Pfizer's Comeback Accelerates
Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion, driven by Abrysvo RSV vaccine and Seagen-acquired oncology assets. Management expects over $20 billion in risk-adjusted r...
Pfizer, partner BioNTech say updated COVID shot shows better immune response
Pfizer and partner BioNTech said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one under...
Is Pfizer a Millionaire Maker?
Pfizer (PFE 1.28%) is a fairly well-known drugmaker, with a name that even non-healthcare-oriented types would likely know. That's a testament to the company's longevity and its success as a business.
Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks
Despite pressure from HHS Secretary RFK Jr. and pessimism from retail investors, Pfizer Inc.'s COVID-19 franchise sales were $808 million in Q2 2025, up 81.2% year-on-year. In addition, its oncolog...
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (September 2025)
Shares of Pfizer ( NYSE: PFE ) gained 4.50% over the past month after losing 6.50% the month prior.
Pfizer: Pipeline Monetization Shows Great Promise - Rich Yields Pending Re-Rating
PFE has shown great efforts in operational efficiencies, as observed in the richer profit margins, the expanding cash flows, and the healthier balance sheet. This is on top of its new pipelines/ pa...
Pfizer's Golden Cross Signals Strength: How to Play the Stock
Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.
3 No-Brainer Stocks to Buy Right Now
Some decisions require lengthy deliberations and extensive analysis. Others don't.
4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer
If you're in the market for some promising dividend-paying stocks, good for you! They can be powerful components in your portfolio, ideally delivering not only regular income but also, over time, a...
Better High-Yielding Dividend Stock: Realty Income vs. Pfizer
Dividend stocks are a great way for investors to generate passive income that can be more reliable and predictable than investing in stocks for pure appreciation. While there are no guarantees in t...
Related Companies